CMS receives FDA clearance for IMRT planning platform
CMS, a provider of radiation treatment planning and workflow management solutions, has received FDA 510(k) clearance for Monaco, its next-generation intensity modulated radiation therapy (IMRT) planning platform, and can now distribute it for clinical use in the United States.

Monaco, developed at the University of Tübingen in Germany in collaboration with Markus Alber, PhD and colleagues, features biological cost functions with multi-criterial constrained optimization, a leaf sequencer and a Monte Carlo dose calculation algorithm, according to the St. Louis-based company.

CMS previously announced the release of Monaco 1.0 in July and the first clinical implementations have already been completed in Europe and Australia.